EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Exploring New Molecular Targets for Anti-cancer Therapy
Clinical Professor, Department of Medicine, University of British Columbia
Amil Shah is Clinical Professor of Medicine at the University of British Columbia His practice focusses on gastrointestinal and lung cancers Among his administrativeacademic roles he chaired the Gastrointestinal Tumour Group at BC Cancer and served as Associate Dean of the VancouverFraser Medical Program at UBC His research interest is the molecular pathogenesis of cancer
Articles
APAC’s Rising Role in Neurodegenerative Disease Research and Development
Neurodegenerative diseases represent one of the most pressing global health challenges of the coming decades driven by aging populations increasing disease prevalence and the absence of curative therapies While historically concentrated in North America and Europe research and development efforts in this field are increasingly expanding toward the AsiaPacific APAC region reflecting broader shifts...
Research Insights
Unveiling Hidden Structural Patterns in the SARS-CoV-2 Genome: Computational Insights and Comparative Analysis
SARSCoV the virus responsible for covid is a member of the clade Betacoronavirus and is a positive sense single stranded RNA virus with a genome size
Case Studies
Ambient Stable Biologics - Stable Aqueous Erythropoietin
Challenge Erythropoietin EPO is known to aggregate under heat stress which prevents storage of liquid compositions at ambient temperature The key challenge of this study was to demonstrate that the application of the ArestatT tools can reduce significantly aggregation of EPO at an elevated temperature compared with a marketed liquid formulation
Techno Trends
Janssen Pharmaceuticals Introduces Novel TALVEY® for the Tretament of Relapsed And Refractory Multiple Myeloma
Janssen Pharmaceuticals a subsidiary of Johnson Johnson has introduced a new treatment TALVEY talquetamab for patients with relapsed and refractory multiple myeloma
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes
Abhinab Goswamiis currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 01 research paper, 02 review articles and 01 book chapter in renowned journals/international book. His research focus lies in developing the neoteric solvents-based injectable dispersions for intra-auricular administration. He has also identified few neoteric solvents potential for converting them into nanomedicines.
Datta Maroti Pawde is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 05 research papers, 05 review articles and 03 book chapters in renowned journals/international book. Using the dual drug-loaded emulsions at lab-and pilot-scale, the intraarticular injections are developed to treat inflammatory conditions produced at articular or periarticular structures.
Syed Nazrin Ruhina Rahman is currently pursuing her Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. She has published 02 research papers, 06 review articles and 04 book chapters in renowned journals/international book. Her research focus lies in managing the dry-eye syndrome by the topical application of cyclosporin A-loaded cationic emulsions.
Faculty Member, SB College of Pharmacy
Tamilvanan Shunmugaperumal is currently working at National Institute of Pharmaceutical Education and Research, Guwahati. He has published 58 research papers, 24 review articles and 08 book chapters in renowned journals international book. He is also author of 07 international books and holding 04 granted patents, 03 copyrights materials, etc.. His industrial-oriented research resulted in transfer of cationic emulsion formula from lab to industry.
USN Murty is currently working as Director of National Institute of Pharmaceutical Education and Research, Guwahati. He is the man of antimalarial research especially finding molecular leads from plant sources. He holds more than 100 research papers, few review articles and granted patents along with copyrights materials. His articulation in bioinformatics subjects is remarkable and he is the ardent user of artificial intelligence and machine learning in health-related platform.
Allosteric Modulation: A Paradigm Shift in Pharmaceutical Innovation
Dr. Parth Sarthi Sen Gupta is a Computational Biologist specializing in computational drug and vaccine design, with a focus on allosteric modulation. He is an Associate professor in School of Biosciences and Bioengineering, D Y Patil International University. He has published more than 50 research articles and book chapter in reputed peer reviewed Journals. His research work on COVID19 has been highlighted by various national and international news agencies and recognized by World health organizations.
Peptide-Drug Conjugates in Precision Oncology
Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.
Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.
Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.
Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”
Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.
Marine Biomaterials for Drug Delivery Applications
Macha has six years of experience in research and teaching in the area of biomaterials synthesis and characterisations, drug delivery devices, cell culture and bacterial biofilm. He is also Associate Editor of the Journal of The Australian Ceramic Society and has published more than 14 articles and 6 book chapters.
Trump Tariff Tyranny and Pharma Preparedness
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
press releasesRead more...
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
Astellas Pharma Inc TSE President and CEO Naoki Okamura Astellas today announced that it has reached an agreement with the US government that reflects our commitment to patient access affordability
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
DUALITYBIO Inc HKEX DualityBio or the Company today announced that it has entered into a collaboration and license agreement with Genentech a member of the Roche Group to develop nextgeneration
Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research
Monash Health the largest public health service in Victoria Australia has signed a Memorandum of Understanding MoU with DataLife an international nonprofit digital health organization funded by the Hasso
HKBU hosts inaugural International Symposium on Innovation and R&D in Traditional Chinese Medicine to promote modernisation, internationalisation and research translation in Chinese medicine
Hong Kong Baptist University HKBU InnoHK Centre for Chinese Herbal Medicine Drug Development CDD coorganised the inaugural International Symposium on Innovation and RD in Traditional
11th Edition Medical Device Project and Portfolio Management
Medical device organizations are under increasing pressure to deliver more innovation with fewer resources while navigating regulatory complexity rising development costs portfolio congestion and growing demands
Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases
Eli Lilly and Company NYSE LLY and Merida Biosciences Inc Merida a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases today announced a definitive agreement for Lilly to acquire Merida
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains
Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102
Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer
Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer
Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients
BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years
Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1
Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults